UCB Research HQ in Surrey Gets a New Contractor after ISG’s Collapse
The construction of UCB’s £60m research and development (R&D) headquarters in Windlesham, Surrey, is back on track. The pharmaceutical giant’s ambitious project faced a major setback when ISG, the initial contractor, collapsed, leaving the site unfinished and uncertain. Now, Walter Lilly, a renowned London-based contractor with extensive experience in complex projects, has stepped in to bring the vision to life.
The vision for Project Apple: A cutting-edge research hub
Known as Project Apple, the new facility is designed to be a centre of excellence for UCB’s R&D activities. The 7,400-square-metre headquarters will feature state-of-the-art laboratories, refurbished R&D buildings, and shared spaces such as a central atrium and an events area. Located on a sprawling 19-hectare site acquired from Eli Lilly and Company, the project reflects UCB’s commitment to pioneering treatments and advancing pharmaceutical innovation.
The Windlesham facility is not only critical for UCB’s global R&D initiatives but also for its role in early manufacturing processes and the commercialisation of breakthrough medicines. Once completed, the site will enhance UCB’s ability to deliver transformative therapies and solidify its presence in the UK’s thriving pharmaceutical sector.
Impact of ISG’s collapse on the construction project
The sudden administration of ISG, one of the UK’s largest contractors, sent shockwaves through the construction industry. For UCB, the collapse created an abrupt pause in the development of its vital research hub. While the details surrounding ISG’s financial difficulties remain complex, its downfall disrupted numerous public and private sector projects, including the Windlesham site.
Transitioning from ISG to Walter Lilly posed significant logistical challenges. Securing a contractor capable of managing such a high-profile and complex development required careful evaluation. The hiatus also delayed UCB’s timeline for operational readiness, impacting its broader R&D strategy.
Walter Lilly’s approach to the project
Walter Lilly has taken on the responsibility of completing UCB’s Windlesham research headquarters. Known for its work in sectors such as pharmaceuticals, education, and luxury residential construction, the firm is uniquely qualified to navigate the complexities of Project Apple.
Upon appointment, Walter Lilly’s immediate priority has been assessing the site’s current state, ensuring the existing structures meet safety and quality standards, and devising a comprehensive plan to resume construction efficiently.
The resumed construction marks a pivotal moment for UCB, as the research hub is critical to the company’s ambitions of advancing pharmaceutical innovation. Once operational, the facility is expected to house hundreds of scientists, researchers, and support staff, contributing significantly to the UK’s biopharmaceutical landscape.
Despite the setbacks caused by ISG’s collapse, UCB and Walter Lilly remain optimistic about the project’s successful delivery. While no official completion date has been confirmed, insiders suggest the site could become operational by late 2025 or early 2026.
Sources:
To keep up-to-date with our latest construction and civil engineering news, subscribe to our newsletter today.